Why the study?
Existing cardiovascular risk prediction models that guide antihypertensive prescription often exclude individuals with prior cardiovascular disease or those on statins, leaving limited evidence on how treatment benefits and harms vary by baseline risk.
Population
5,578,002 patients aged >=40 years from the Clinical Practice Research Datalink (1998-2018)
Design
Cohort modelling study with model development (CPRD GOLD) and external validation (Aurum dataset)
Answers are grounded in this paper and cite their sources.
Supports risk-stratified antihypertensive decisions in primary care; extends prior models but remains hypothesis-generating pending randomized data.
Antihypertensive prescription is guided by cardiovascular risk prediction models. However, existing models often exclude individuals with prior cardiovascular disease or those prescribed statin treatment. Consequently, there is limited evidence regarding how the benefits and harms of treatment vary according to an individual’s baseline risk. This cohort study includes 5,578,002 patients aged≥40years (mean age 59; 52% women) from the Clinical Practice Research Datalink between 1998–2018. A cardiovascular risk prediction model is developed using the Clinical Practice Research Datalink GOLD dataset and externally validated using the Aurum dataset. The model demonstrates excellent calibration and discrimination. Antihypertensive therapy is more likely to prevent serious major cardiovascular events (eight events prevented per 1,000 patients over 10 years, 95% confidence interval = 1 to 14), than to cause serious falls (two events per 1,000 patients, 95% confidence interval = −4 to 10). The risks of other adverse events indicate more nuanced or potentially harmful trade-offs. Here we show that a cardiovascular risk prediction model developed using routinely collected primary care data accurately predicts risk across a broad population of patients eligible for antihypertensive treatment. These findings will enable clinicians to better communicate individualised benefits and risks of antihypertensive therapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: